Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lyell ImmunopharmaLYEL +1.47%55 Current Ratio is 7.23 as of Mar. 2026, which is 45% below its 10-year median of 13.26. GuruFocus rates LYEL with a GF Score™ of 55/100 and a GF Value™ of $5.26 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,411 Biotechnology companies, Lyell Immunopharma ranks better than 69.24% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Lyell Immunopharma's current ratio for the quarter that ended in Mar. 2026 was 7.23.
Lyell Immunopharma has a current ratio of 7.23. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Lyell Immunopharma's Current Ratio or its related term are showing as below:
LYEL'
s Current Ratio Range Over the Past 10 Years
Min: 5.28 Med: 13.26 Max: 20.27
Current: 7.23
During the past 7 years, Lyell Immunopharma's highest Current Ratio was 20.27. The lowest was 5.28. And the median was 13.26.
LYEL's Current Ratio is ranked better than 69.24% of 1411
companies
in the Biotechnology industry
Industry Median: 3.88
vs LYEL: 7.23
Lyell Immunopharma (NAS:LYEL) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Lyell Immunopharma Current Ratio Related Terms
Lyell Immunopharma Current Ratio Historical Data
* Premium members only.
The historical data trend for Lyell Immunopharma's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LYEL vs ALXO, ARMP, NAGE: Current Ratio Comparison
For the Biotechnology subindustry, Lyell Immunopharma's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lyell Immunopharma Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lyell Immunopharma's Current Ratio distribution charts can be found below:
* The bar in red indicates where Lyell Immunopharma's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lyell Immunopharma (LYEL) has a Current Ratio of 7.23 as of Mar. 2026. This is 45% below median its historical median of 13.26. Over the past decade, Lyell Immunopharma's Current Ratio has ranged from 5.28 to 20.27. According to the industry distribution chart, Lyell Immunopharma ranks #434 out of 1411 companies in the Biotechnology industry, placing it in the top 30.8%.
Is Lyell Immunopharma's Current Ratio too high?
Lyell Immunopharma's current Current Ratio of 7.23 is 45% below median its 10-year median of 13.26. Over the past 10 years, this metric has ranged from a low of 5.28 to a high of 20.27. The Biotechnology industry median Current Ratio is 3.88. Lyell Immunopharma's value of 7.23 is 86.3% above this industry median. Based on the distribution chart, Lyell Immunopharma ranks #434 out of 1411 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Lyell Immunopharma has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lyell Immunopharma's Current Ratio compare to ALXO and ARMP?
According to the Biotechnology industry distribution chart, Lyell Immunopharma ranks #434 out of 1411 companies for Current Ratio. This puts Lyell Immunopharma in the upper half of its industry. The industry median Current Ratio is 3.88. Lyell Immunopharma's value of 7.23 is 86.3% above this benchmark. Historically, Lyell Immunopharma's own Current Ratio has ranged from 5.28 to 20.27 over the past decade. While the company's 10-year median is 13.26 vs. the industry median of 3.88, Lyell Immunopharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.88, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lyell Immunopharma's current Current Ratio of 7.23 is 86.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lyell Immunopharma's current Current Ratio is 7.23, which is 45% below median its own 10-year median of 13.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lyell Immunopharma stock overvalued right now?
Based on GuruFocus' analysis, Lyell Immunopharma (LYEL) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.26, compared to a current price of $13.19 — trading 150.8% above its estimated fair value. The current Current Ratio is 7.23, which is 45% below median its 10-year median of 13.26 and 86.3% above the Biotechnology industry median of 3.88. Lyell Immunopharma's overall GF Score™ is 55/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Lyell Immunopharma (LYEL), the current Current Ratio is 7.23 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lyell Immunopharma (LYEL) Overvalued in 2026?
Based on GuruFocus' analysis, Lyell Immunopharma stock appears to be overvalued.
The current stock price of $13.19 is trading 150.8% above its estimated GF Value™ of $5.26.
GuruFocus considers Lyell Immunopharma to be Significantly Overvalued.
Key valuation signals for LYEL:
Current Ratio: 7.23 (45% below median its 10-year median of 13.26)
GF Value™: $5.26 vs. price of $13.19 (150.8% above fair value)
Industry Position: 86.3% above the Biotechnology median (#434 of 1411)
No single metric tells the full story. See the LYEL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
55GF Score
Get the complete analysis for LYEL
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LYEL has been successfully added to your 
